@article{a741e06ccf7248648b39223b87caa805,
title = "Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.",
author = "A. Vashishtha and Patel, \{P. H.\} and W. Yu and Bothos, \{J. G.\} and J. Simpson and T. Maneatis and L. Doessegger and Peterson, \{A. C.\} and C. Clement-Duchene and G. Robinet and M. Krzakowski and Blumenschein, \{G. R.\} and Goldschmidt, \{J. H.\} and Daniel, \{D. B.\} and Spigel, \{D. R.\}",
note = "7604 Background: MetMAb (M) is a monovalent monoclonal antibody that blocks HGF-induced Met signaling. A Phase II double-blinded, randomized trial of MetMAb+erlotinib (M+E) or placebo+erlotinib (P+E) in 2nd- and /3rd- line NSCLC was recently completed. The M+E arm demonstrated both PFS and OS advantages in the c-Met IHC expression positive 2+ /3+ (Met Dx+) patients only.",
year = "2011",
month = may,
day = "20",
doi = "10.1200/JCO.2011.29.15\_SUPPL.7604",
language = "American English",
volume = "29",
journal = "Journal of Clinical Oncology",
}